<?xml version="1.0" encoding="UTF-8"?>
<table id="PMC7128376/table_2" xmlns="http://www.w3.org/1999/xhtml">
 <caption>
  <label>Table 2</label>
  <p>The detailed report of commercially available drugs in treatment of COVID–19.</p>
 </caption>
 <thead>
  <tr>
   <th colspan="1" rowspan="1" id="0-0-.">S. no.</th>
   <th colspan="1" rowspan="1" id="0-1-.">Name of drug</th>
   <th colspan="1" rowspan="1" id="0-2-.">Illnesses treated</th>
   <th colspan="1" rowspan="1" id="0-3-.">References</th>
  </tr>
 </thead>
 <tbody>
  <tr>
   <td>1.</td>
   <td>α-Interferon</td>
   <td>Spectrum of respiratory infections, RSV and SARS</td>
   <td>( 
    <a rid="bb0140" ref-type="bibr">Cinatl et al., 2003</a>; 
    <a rid="bb6000" ref-type="bibr">Guerrero et al., 2013</a>; 
    <a rid="bb0525" ref-type="bibr">Markland et al., 2000</a>) 
   </td>
  </tr>
  <tr>
   <td>2.</td>
   <td>Ritonavir and lopinavir</td>
   <td>SARS, MERS</td>
   <td>( 
    <a rid="bb0135" ref-type="bibr">Chu et al., 2004</a>) 
   </td>
  </tr>
  <tr>
   <td>3.</td>
   <td>Ribavirin</td>
   <td>RSV and RSV pneumonia</td>
   <td>( 
    <a rid="bb0425" ref-type="bibr">Lewinsohn et al., 1996</a>; 
    <a rid="bb0540" ref-type="bibr">McIntosh et al., 1984</a>) 
   </td>
  </tr>
  <tr>
   <td>4.</td>
   <td>Reverse transcriptase inhibitors: zidovudine, didanosine, zalcitabine, stavudine, lamivudine, abacavir and emtricitabine.</td>
   <td>SARS</td>
   <td>( 
    <a rid="bb0175" ref-type="bibr">De Clercq, 2007</a>) 
   </td>
  </tr>
  <tr>
   <td>5.</td>
   <td>Nucleotide reverse transcriptase inhibitor: tenofovir disoproxil fumarate.</td>
   <td>SARS</td>
   <td>( 
    <a rid="bb0175" ref-type="bibr">De Clercq, 2007</a>) 
   </td>
  </tr>
  <tr>
   <td>6.</td>
   <td>Non-nucleoside reverse transcriptase inhibitors (NNRTIs): nevirapine, delavirdine and efavirenz.</td>
   <td>SARS</td>
   <td>
    <a rid="bb0175" ref-type="bibr">De Clercq, 2007</a>
   </td>
  </tr>
  <tr>
   <td>7.</td>
   <td>Protease Inhibitors (PIs): saquinavir, ritonavir, indinavir, nelfinavir, amprenavir, lopinavir, atazanavir and fosamprenavir.</td>
   <td>SARS</td>
   <td>
    <a rid="bb0175" ref-type="bibr">De Clercq, 2007</a>
   </td>
  </tr>
  <tr>
   <td>8.</td>
   <td>Fusion inhibitor: enfuvirtide. Lamivudine and adefovir dipivoxil.</td>
   <td>SARS</td>
   <td>
    <a rid="bb0175" ref-type="bibr">De Clercq, 2007</a>
   </td>
  </tr>
  <tr>
   <td>9.</td>
   <td>Umifenovir</td>
   <td>ARVI, influenza, rhinovirus, adenovirus, parainfluenza, respiratory syncytial virus, coronavirus, including the causative agent of atypical pneumonia 
    <br/>Used in the phase III trials of 2019- nCoV virus, SARS, MERS 
   </td>
   <td>( 
    <a rid="bb0175" ref-type="bibr">De Clercq, 2007</a>) 
   </td>
  </tr>
  <tr>
   <td>10.</td>
   <td>3-Chymotrypsin-like protease</td>
   <td>SARS, MERS</td>
   <td>( 
    <a rid="bb0130" ref-type="bibr">Chou et al., 2008</a>; 
    <a rid="bb0400" ref-type="bibr">Kilianski et al., 2013</a>; 
    <a rid="bb0435" ref-type="bibr">Li and Clercq, 2020</a>) 
   </td>
  </tr>
  <tr>
   <td>11.</td>
   <td>Papain-like protease</td>
   <td>SARS, MERS and Human Coronavirus NL63.</td>
   <td>( 
    <a rid="bb0115" ref-type="bibr">Chen, 2020</a>; 
    <a rid="bb0290" ref-type="bibr">Harcourt et al., 2004</a>; 
    <a rid="bb0400" ref-type="bibr">Kilianski et al., 2013</a>) 
   </td>
  </tr>
  <tr>
   <td>12.</td>
   <td>RNA-dependent RNA polymerase</td>
   <td>SARS, Murine Coronavirus.</td>
   <td>( 
    <a rid="bb0335" ref-type="bibr">Imbert et al., 2006</a>; 
    <a rid="bb0490" ref-type="bibr">Lu, 2020</a>; 
    <a rid="bb0500" ref-type="bibr">Mahy et al., 1983</a>) 
   </td>
  </tr>
  <tr>
   <td>13.</td>
   <td>Capsid spike glycoprotein (hCoV-EMC)</td>
   <td>SARS, Human Coronavirus</td>
   <td>( 
    <a rid="bb0240" ref-type="bibr">Gierer et al., 2013</a>; 
    <a rid="bb0305" ref-type="bibr">Hoffmann et al., 2020</a>; 
    <a rid="bb0310" ref-type="bibr">Howard et al., 2008</a>) 
   </td>
  </tr>
  <tr>
   <td>14.</td>
   <td>Guanosine-analog RNA synthesis inhibitors</td>
   <td>Coronavirus</td>
   <td>( 
    <a rid="bb0055" ref-type="bibr">Beaucourt and Vignuzzi, 2014</a>) 
   </td>
  </tr>
  <tr>
   <td>15.</td>
   <td>Nitazoxanide</td>
   <td>SARS, MERS and Influenza</td>
   <td>( 
    <a rid="bb0660" ref-type="bibr">Rossignol, 2016</a>) 
   </td>
  </tr>
  <tr>
   <td>16.</td>
   <td>Influenza drugs</td>
   <td>MERS</td>
   <td>( 
    <a rid="bb0175" ref-type="bibr">De Clercq, 2007</a>) 
   </td>
  </tr>
  <tr>
   <td>17.</td>
   <td>Remdesivir</td>
   <td>COVID-19, SARS, MERS</td>
   <td>
    <a rid="bb6005" ref-type="bibr">Agostini et al., 2018</a>; 
    <a rid="bb0795" ref-type="bibr">Wang, 2020</a>
   </td>
  </tr>
  <tr>
   <td>18.</td>
   <td>Favipiravir</td>
   <td>COVID-19</td>
   <td>( 
    <a rid="bb0795" ref-type="bibr">Wang, 2020</a>) 
   </td>
  </tr>
  <tr>
   <td>19.</td>
   <td>Darunavir</td>
   <td>COVID-19</td>
   <td>( 
    <a rid="bb0060" ref-type="bibr">Beck et al., 2020</a>; 
    <a rid="bb0450" ref-type="bibr">Lin et al., 2020</a>) 
   </td>
  </tr>
  <tr>
   <td>20.</td>
   <td>Lopinavir</td>
   <td>COVID-19, SARS, MERS</td>
   <td>
    <a rid="bb6010" ref-type="bibr">Yao et al., 2020</a>
   </td>
  </tr>
  <tr>
   <td>21.</td>
   <td>Alcohol Vaporization or Nebulization Inhalation Therapy</td>
   <td>COVID-19</td>
   <td>( 
    <a rid="bb0085" ref-type="bibr">Cao, 2020</a>) 
   </td>
  </tr>
  <tr>
   <td>22.</td>
   <td>Chloroquine</td>
   <td>SARS, Human Coronavirus OC43.</td>
   <td>( 
    <a rid="bb0390" ref-type="bibr">Keyaerts et al., 2009</a>, 
    <a rid="bb0380" ref-type="bibr">Keyaerts et al., 2004</a>; 
    <a rid="bb0775" ref-type="bibr">Vincent et al., 2005</a>) 
   </td>
  </tr>
  <tr>
   <td>23.</td>
   <td>ASC09</td>
   <td>ARDS, Respiratory distress syndrome, SARS, MERS</td>
   <td>( 
    <a rid="bb0520" ref-type="bibr">March and Bogatcheva, 2018</a>, 
    <a rid="bb7000" ref-type="bibr">March and Bogatcheva, 2019</a>) 
   </td>
  </tr>
  <tr>
   <td>24.</td>
   <td>TMPRSS2 inhibitor Camostat mesylate</td>
   <td>SARS, MERS, Coronavirus 229E and COVID-19</td>
   <td>( 
    <a rid="bb0065" ref-type="bibr">Bertram et al., 2013</a>; 
    <a rid="bb0305" ref-type="bibr">Hoffmann et al., 2020</a>; 
    <a rid="bb0375" ref-type="bibr">Kawase et al., 2012</a>; 
    <a rid="bb0695" ref-type="bibr">Shirato et al., 2014</a>) 
   </td>
  </tr>
  <tr>
   <td>25.</td>
   <td>Baricitinib</td>
   <td>COVID-19</td>
   <td>( 
    <a rid="bb0655" ref-type="bibr">Richardson et al., 2020</a>; 
    <a rid="bb0725" ref-type="bibr">Stebbing et al., 2020</a>) 
   </td>
  </tr>
  <tr>
   <td>26.</td>
   <td>Ruxolitinib</td>
   <td>COVID-19</td>
   <td>( 
    <a rid="bb0725" ref-type="bibr">Stebbing et al., 2020</a>) 
   </td>
  </tr>
  <tr>
   <td>27.</td>
   <td>Saquinavir</td>
   <td>SARS and Feline Coronavirus</td>
   <td>( 
    <a rid="bb0070" ref-type="bibr">Blanchard et al., 2004</a>; 
    <a rid="bb0145" ref-type="bibr">Comper, 2005</a>; 
    <a rid="bb0315" ref-type="bibr">Hsieh et al., 2010</a>) 
   </td>
  </tr>
  <tr>
   <td>28.</td>
   <td>Indinavir</td>
   <td>SARS and COVID-19</td>
   <td>( 
    <a rid="bb0150" ref-type="bibr">Contini, 2020</a>; 
    <a rid="bb0750" ref-type="bibr">Tan et al., 2004</a>) 
   </td>
  </tr>
  <tr>
   <td>29.</td>
   <td>Carfilzomib</td>
   <td>COVID-19</td>
   <td>( 
    <a rid="bb0795" ref-type="bibr">Wang, 2020</a>) 
   </td>
  </tr>
  <tr>
   <td>30.</td>
   <td>Oseltamivir</td>
   <td>COVID-19</td>
   <td>( 
    <a rid="bb0280" ref-type="bibr">Haagmans et al., 2004</a>; 
    <a rid="bb0490" ref-type="bibr">Lu, 2020</a>) 
   </td>
  </tr>
  <tr>
   <td>31.</td>
   <td>Azvudine</td>
   <td>COVID-19</td>
   <td>( 
    <a rid="bb0320" ref-type="bibr">Hu et al., 2020</a>) 
   </td>
  </tr>
  <tr>
   <td>32.</td>
   <td>Baloxavir marboxil</td>
   <td>COVID-19</td>
   <td>( 
    <a rid="bb0435" ref-type="bibr">Li and Clercq, 2020</a>) 
   </td>
  </tr>
  <tr>
   <td>33.</td>
   <td>Thymosin α1</td>
   <td>MERS</td>
   <td>( 
    <a rid="bb0430" ref-type="bibr">Leyva-Grado and Behzadi, 2019</a>) 
   </td>
  </tr>
  <tr>
   <td>34.</td>
   <td>Methylprednisolone</td>
   <td>SARS, MERS</td>
   <td>( 
    <a rid="bb6020" ref-type="bibr">Kim et al., 2016</a>; 
    <a rid="bb0635" ref-type="bibr">Que et al., 2003</a>) 
   </td>
  </tr>
  <tr>
   <td>35.</td>
   <td>Tocilizumab</td>
   <td>COVID-19</td>
   <td>( 
    <a rid="bb0190" ref-type="bibr">Diao et al., 2020</a>) 
   </td>
  </tr>
  <tr>
   <td>36.</td>
   <td>Interferon Subtypes of β-1b, α-n1, α-n3, and human leukocyte interferon α</td>
   <td>SARS</td>
   <td>( 
    <a rid="bb0750" ref-type="bibr">Tan et al., 2004</a>) 
   </td>
  </tr>
  <tr>
   <td>37.</td>
   <td>Acyclovir</td>
   <td>SARS, MERS, Coronavirus 229E and COVID-19</td>
   <td>( 
    <a rid="bb0615" ref-type="bibr">Peters et al., 2015</a>) 
   </td>
  </tr>
  <tr>
   <td>38.</td>
   <td>Cathespin L</td>
   <td>SARS</td>
   <td>( 
    <a rid="bb6025" ref-type="bibr">Simmons et al., 2005</a>) 
   </td>
  </tr>
 </tbody>
 <tfoot>
  <p class="fn" charset="fn">
   <p>This table represents the commercially available drugs used for the treatment of the various forms of coronaviruses. The viral infections discussed in the table are SARS - Severe Acute Respiratory Syndrome, MERS - Middle East Respiratory Syndrome, RSV - Respiratory Syncytial Virus, ARVI - Acute respiratory viral infections.</p>
  </p>
 </tfoot>
</table>
